These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 38807)

  • 1. [Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)].
    Schilkrut R; Duran E; Haverbeck C; Katz I; Vidal P
    Arzneimittelforschung; 1978; 28(9):1494-5. PubMed ID: 38807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
    Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA
    Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 4. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
    Dufresne RL; Wagner RL
    J Clin Psychiatry; 1988 Nov; 49(11):435-8. PubMed ID: 2903141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients].
    Ginzel I; Hilger E; Barnas C
    Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication].
    Steuber H; Kind J; Lohrengel S; Müller P
    Arzneimittelforschung; 1978; 28(9):1492-3. PubMed ID: 38806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
    Perez V; Cañas F; Tafalla M;
    Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
    Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
    Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of clozapine on neuroleptigenic extrapyramidal motor disturbances (author's transl)].
    Zander KJ; Rüther E
    Arzneimittelforschung; 1978; 28(9):1495-6. PubMed ID: 38808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.